BioMed Research International · 2019 · 30 citations · 25 references
PharmacyInfectious DiseasesPharmacoeconomicsAntimicrobial ResistanceAntimicrobial Resistance EpidemiologyCost-effectiveness AnalysisAntibiotic ResistanceDirect Medical CostsHealth Care CostsHealthcare Cost AnalysisMultidrug ResistancePharmacoeconomic EvaluationDirect CostsDrug Cost AnalysisDrug Resistance BurdenEconomic Burden Of DiseaseEconomic Burden Of IllnessHealthcare Cost ImpactMedical Cost AnalysisMultidrug-resistant Organisms
Healthcare associated infection (HAI) is known to increase the economic burden of patients while the medical cost due to MDRO HAI is even higher. Three hundred eighty-one multidrug resistance organisms (MDROs) healthcare associated infection (HAI) case-patients and three hundred eighty-one matched control-patients were identified between January and December in 2015. The average total hospitalization medical cost of the case group was $6127.65 and that of the control group was $2274.02. The difference between the case group and the control group was statistically significant (t = 21.07; P < 0.01). The attributable cost of MDRO HAI was $3853.63. The direct medical costs due to different MDRO infections were different. The increased medical costs of CR-AB, CR-KP, and CR-PA were significantly higher than that of MRSA, MRSE, ESBL E. coli, and ESBL Kp (P < 0. 05). Among the subitem expenses, the drug cost increased the most (the average cost was $1457.72), followed by the treatment fee and test fee; the differences were statistically significant (P < 0.01).
25
John J. Engemann, Yehuda Carmeli, Sara E. Cosgrove et al. · Clinical Infectious Diseases · 2003 · 938 citations · Full text
Sara E. Cosgrove, Youlin Qi, Keith S. Kaye et al. · Infection Control and Hospital Epidemiology · 2005 · 862 citations